Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. - Wikidata - awgldk - TriplyDB

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

http://www.wikidata.org/entity/Q34026627

about

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.Predicting neutropenia risk in patients with cancer using electronic data.The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.The Emergency Care of Patients With Cancer: Setting the Research Agenda.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.Infection-related mortality in Hispanic and non-Hispanic children with cancer.The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

P2860

Q26768126-14416D51-C4B3-48FC-8E14-8372EF5E3824 Q30416074-38ADC497-F14C-447D-96E8-C92126F8AB39 Q31131362-08EFB18B-E841-4869-8871-84FDC9B3FB69 Q33440800-0D4837B2-B1DE-45E9-9277-90E0E3C21070 Q33557215-D85038D0-E37E-4A8B-842D-3263F9D8D04E Q33778817-326BFFC7-C91C-479A-9876-440E2AB54B89 Q34184798-75C8E7D6-4C4C-4E83-9CA0-E16C0E74B6D3 Q34553998-BB9D8444-4D6B-4C46-9D01-9D29D9B0CCF9 Q34631769-38D92F8A-673B-4C97-B908-65CBD66CD8C1 Q34670717-FA37E3A5-D6FF-4015-9D20-108824A58937 Q35123683-D8AABABE-026E-4156-AF7C-ECC7BA2D1708 Q35165571-BE5EF7BD-F235-41F0-93B4-4D13C27ACBB2 Q35165579-DE5C599A-C032-4558-B930-FC7540401464 Q35862322-F4913235-1F48-42A7-BDF7-075909F07220 Q36023851-663D4D6B-9001-46A4-BCD7-51B7C2437011 Q36076727-8FC38474-EFD8-4EEA-BBC5-0B7FC8B961BC Q36243957-DB4CFED1-4C37-4577-BBCC-BCCD1050B8FF Q36897773-8D0A4478-E73B-4111-9330-6C4E1C85DF0C Q37205943-5E4F8B20-8E89-4A7C-9175-37AAC38E854A Q37211558-D94FE7B1-DCD8-4007-A5E4-A858A6A1D68D Q37554901-6F421A04-A32E-4855-A32B-AEE373794FA2 Q37703409-539BD147-A733-411A-8172-69F2D68752E8 Q37996443-4D4D5495-3D3B-4B04-8080-AE60B6976238 Q38006021-1363EAA0-417F-487D-809C-9B0E89A242C0 Q38084890-72A0A85C-AAE4-4374-AC6E-CBCDEB44A8C2 Q38085227-AE6EFD7D-431C-41D0-B669-F9B91F974B0D Q38109529-4E4F9201-F42A-4784-83BB-250E090C9FA7 Q38256944-B0A846F8-9759-4FA5-AA0C-176800C27ED4 Q38309710-450C109A-A20B-41E0-892A-992BBB842F3C Q38682028-BDB49E63-B32C-4E0F-8D43-8691BBB6CF65 Q38711166-984A90F6-ABD1-4A7B-A301-BF06DC5DC667 Q40108064-3B8B8D7C-F76F-4673-AD22-6463D268AF9B Q40222201-DE6A88EB-0DEC-46AA-884E-B9A21FF38E4A Q40240367-2DE22E81-A512-471B-91D0-CD92CCD5439D Q40306765-1C27DD7F-7C69-4512-B881-286A164482DB Q40307046-52249537-CB7D-4C10-A442-5DC08B9F8334 Q40829486-A8A1D4F2-B913-4525-91B3-E5A51C1D761A Q41349270-2010E030-D8E5-4E96-A571-F993DCA22B89 Q42223844-C17E77B5-27AE-4ECA-8904-A7C514C37552 Q42766829-C02DEFAE-D488-422A-909B-8D76A030A3E6

P2860

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

http://www.wikidata.org/entity/Q34026627

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Predicting individual risk of ...... receiving cancer chemotherapy.

@ast

Predicting individual risk of ...... receiving cancer chemotherapy.

@en

Predicting individual risk of ...... receiving cancer chemotherapy.

@nl

type

label

Predicting individual risk of ...... receiving cancer chemotherapy.

@ast

Predicting individual risk of ...... receiving cancer chemotherapy.

@en

Predicting individual risk of ...... receiving cancer chemotherapy.

@nl

prefLabel

Predicting individual risk of ...... receiving cancer chemotherapy.

@ast

Predicting individual risk of ...... receiving cancer chemotherapy.

@en

Predicting individual risk of ...... receiving cancer chemotherapy.

@nl

P1433

Q34026627-618E69EB-71D9-4C93-A6E7-0EDB7F2867B5

P1476

Q34026627-EDF094F4-FF31-42ED-B073-1493EDC3C5A3

P2093

Q34026627-0A3434A6-FD93-43F9-A296-DF478284A026

Q34026627-189FB8C0-F06B-4932-9EB2-279F81EA0ECB

Q34026627-1DBB787C-2B4E-4E6D-B703-651E677FD73C

Q34026627-26DD01A3-CF4C-4D8C-8056-B0F346246EA5

Q34026627-2E5F3548-060C-4C3D-883A-567F7B33117C

Q34026627-6119C4F1-AA61-4E5C-B934-87B49AE0A59C

Q34026627-CA52BF58-5967-4A22-B8B1-BA310D5A8338

P2860

Q34026627-0E657EAA-08F0-4585-B930-06A65048D594

Q34026627-181CCE99-048C-4B2C-9483-F04A11E648CD

Q34026627-1FAA8EAC-E58A-42DB-B86E-A42BA8DBF948

Q34026627-25B6A65A-A146-4D42-B69D-7E6297BE6AAA

Q34026627-2C4ABABC-9D1A-4569-A735-5B961F337A98

Q34026627-32CBB57C-43DA-4459-8F60-49BD052B14A9

Q34026627-664F9165-FF70-4CB4-BCB1-23C1965A649A

Q34026627-761896BB-20FD-4FD0-950B-6546379390C3

Q34026627-76994BCD-A83F-4896-969A-1C0FFBB8A154

Q34026627-824C57D0-488E-4BBE-B8D4-E1227C77E038

P304

Q34026627-60D9E4F2-E5BD-4E48-BF77-287E4B6CBBB7

P31

Q34026627-803CFE37-B203-4269-B1DA-8EC9CAF70E47

P356

Q34026627-DE9383F6-5B67-48AF-9099-8A9424183DE5

P407

Q34026627-A9D5B6F9-B256-4A0D-8453-F3D3C1343F18

P433

Q34026627-7C74F66A-3B4C-4055-BE28-6DB73F79356B

P478

Q34026627-A034A909-F69D-4719-AB6A-47B73780BF9A

P577

Q34026627-9947D667-AC22-4FFD-B45B-2B13E9BF19A2

P5875

Q34026627-CDB55411-B707-47CD-9C6E-3600AEDA8EAC

P698

Q34026627-2FE2F255-3B34-4AAF-9CB5-592F58D34638

P921

Q34026627-4B20074A-05CC-4C93-8915-66BEDB90792B

Q34026627-4BD314CD-BBF1-40CE-ABF3-8B0BB7A6FE1F

P932

Q34026627-2FE50D53-D77C-402B-9E90-A9F13B1F725A

P356

P1433

P1476

Predicting individual risk of ...... receiving cancer chemotherapy.

@en

P2093

David C Dale

http://www.w3.org/2001/XMLSchema#string

Debra A Wolff

http://www.w3.org/2001/XMLSchema#string

Eva Culakova

http://www.w3.org/2001/XMLSchema#string

Gary H Lyman

http://www.w3.org/2001/XMLSchema#string

Jeffrey Crawford

http://www.w3.org/2001/XMLSchema#string

Marek S Poniewierski

http://www.w3.org/2001/XMLSchema#string

Nicole M Kuderer

http://www.w3.org/2001/XMLSchema#string

P2860

No adjustments are needed for multiple comparisons

What's wrong with Bonferroni adjustments.

Prediction of creatinine clearance from serum creatinine

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.

Hematopoietic growth factors in the older cancer patient.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Impact of chemotherapy dose intensity on cancer patient outcomes.

Risk assessment in oncology clinical practice. From risk factors to risk models.

P304

1917-1927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25691

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51067161

http://www.w3.org/2001/XMLSchema#string

P698

21509769

http://www.w3.org/2001/XMLSchema#string

P921

P932

3640637

http://www.w3.org/2001/XMLSchema#string